Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.

Journal Article (Journal Article)

BACKGROUND: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, collected alongside the clinician-reported Common Terminology Criteria for Adverse Events, enables comparisons of patient and clinician reports on treatment toxicity. METHODS: In a multisite study of women receiving chemotherapy for early-stage breast cancer, symptom reports were collected on the same day from patients and their clinicians for 17 symptoms; their data were not shared with each other. The proportions of moderate, severe, or very severe patient-reported symptom severity were compared with the proportions of clinician-rated grade 2, 3, or 4 toxicity. Patient-clinician agreement was assessed via κ statistics. Chi-square tests investigated whether patient characteristics were associated with patient-clinician agreement. RESULTS: Among 267 women, the median age was 58 years (range, 24-83 years), and 26% were nonwhite. There was moderate scoring agreement (κ = 0.413-0.570) for 53% of symptoms, fair agreement for 41% (κ = 0.220-0.378), and slight agreement for 6% (κ = 0.188). For example, patient-reported and clinician-rated percentages were 22% and 8% for severe or very severe fatigue, 41% and 46% for moderate fatigue, 32% and 39% for mild fatigue, and 6% and 7% for none. Clinician severity scores were lower for nonwhite patients in comparison with white patients for peripheral neuropathy, nausea, arthralgia, and dyspnea. CONCLUSIONS: Although clinician reporting of symptoms is common practice in oncology, there is suboptimal agreement with the gold standard of patient self-reporting. These data provide further evidence supporting the integration of patient-reported outcomes into oncological clinical research and clinical practice to improve monitoring of symptoms as well as timely interventions for symptoms.

Full Text

Duke Authors

Cited Authors

  • Nyrop, KA; Deal, AM; Reeve, BB; Basch, E; Chen, YT; Park, JH; Shachar, SS; Carey, LA; Reeder-Hayes, KE; Dees, EC; Jolly, TA; Kimmick, GG; Karuturi, MS; Reinbolt, RE; Speca, JC; Lee, JT; Wood, WA; Muss, HB

Published Date

  • July 1, 2020

Published In

Volume / Issue

  • 126 / 13

Start / End Page

  • 3084 - 3093

PubMed ID

  • 32315091

Pubmed Central ID

  • PMC7931261

Electronic International Standard Serial Number (EISSN)

  • 1097-0142

Digital Object Identifier (DOI)

  • 10.1002/cncr.32898


  • eng

Conference Location

  • United States